MARC details
| 000 -LEADER |
|---|
| fixed length control field |
04604cam a22003134a 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
OSt |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20240116084205.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
071023s2009 pauab b 001 0 eng |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9781416032915 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
1416032916 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9781416060987 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
1416060987 |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
BUL |
| Transcribing agency |
BUL |
| Modifying agency |
BUL |
| Language of cataloging |
eng |
| Description conventions |
rda |
| 082 ## - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
QV 4 W164p 2009 |
| 100 ## - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Waldman, Scott A. |
| 245 00 - TITLE STATEMENT |
|---|
| Title |
Pharmacology and therapeutics : |
| Remainder of title |
principles to practice / |
| Statement of responsibility, etc. |
Scott A. Waldman, Andre Terzic. |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Place of publication, distribution, etc. |
Philadelphia, PA : |
| Name of publisher, distributor, etc. |
Saunders/Elsevier, |
| Date of publication, distribution, etc. |
c2009. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
xix, 1378 p. : |
| Other physical details |
col. ill., col. maps ; |
| Dimensions |
29 cm. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc. note |
Includes bibliographical references and index. |
| 505 ## - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
PART I: PRINCIPLES<br/>Section 1: Pharmacotherapeutic Continuum<br/>1 Drug Discovery<br/>2 Drug Development<br/>3 Regulations and Pharmacovigilence<br/>4 Evidence-Based Drug Utilization<br/><br/>Section 2: Molecular Pharmacology<br/>5 Drug-Receptor Interactions<br/>6 Signal Transduction<br/>7 "Cell Cycle Pharmacology, Antiproliferation, and Apoptosis"<br/><br/>Section 3: Systems Pharmacology<br/>8 Neurotransmitters<br/>9 Autonomic Pharmacology<br/>10 Fluid and Electrolyte Homeostasis<br/>11 Inflammation and Immunomodulation<br/>12 Pharmacobiology of Infections<br/><br/>Section 4: Clinical Pharmacology<br/>13 Pharmacokinetics<br/>14 Pharmacodynamics<br/>15 Pharmacogenetics and Pharmacogenomics<br/>16 Heterogenity of Drug Responses and Individualization of Therapy<br/>17 Pediatric Pharmacology<br/>18 Gender Influences on Pharmacology<br/>19 Pharmacology Across the Aging Continuum<br/>20 Adverse Drug Reactions and Interactions<br/>21 Therapeutic Monitoring<br/><br/>PART II: Practice<br/>Section 5: Cardiovascular Therapeutics<br/>22 Hypertension<br/>23 Dyslipidemias<br/>24 Coronary Artery Disease<br/>25 Rhythm Disorders<br/>26 Heart Failure<br/><br/>Section 6: Pulmonary Therapeutics<br/>27 Pulmonary Arterial Hypertension<br/>28 Asthma and Chronic Obstructive Pulmonary Disease<br/><br/>Section 7: Renal Therapeutics<br/>29 Renal Insufficiency<br/>30 Voiding Dysfunction<br/><br/>Section 8: Gastroenterologic Therapeutics<br/>31 Acid Reflux and Ulcer Disease<br/>32 Motility Disorders<br/>33 Inflammatory Bowel Diseases<br/>34 Hepatic Cirrhosis<br/>35 Infectious Hepatitis<br/><br/>Section 9: Endocrinologic Therapeutics<br/>36 Obesity and Nutrition<br/>37 Diabetes Mellitus<br/>38 Disorders of the Thyroid<br/>39 Disorders of Calcium Metabolism and Bone Mineralization<br/>40 Disorders of the Hypothalamic Pituitary Axis<br/>41 Adrenal Disorders<br/>42 Reproductive Health<br/><br/>Section 10: Neuropharmacologic Therapeutics<br/>43 Alzheimer's Disease and Dementias<br/>44 Parkinson's Disease<br/>45 Seizure Disorders<br/>46 Multiple Sclerosis<br/>47 Dysautonomias<br/>48 Headache<br/>49 Stroke<br/><br/>Section 11: Psychopharmacologic Therapeutics<br/>50 Obsessive-Compulsive Disorders<br/>51 Attention-Deficit/Hyperactivity Disorder<br/>52 Anxiety<br/>53 Depression and Bipolar Disorders<br/>54 Psychosis and Schizophrenia<br/>55 Drug Addiction<br/>56 Nicotine Dependence<br/>57 Insomnia (Narcolepsy)-Related Disorders<br/><br/>Section 12: Ophthalmologic Therapeutics<br/>58 Drugs in Ophthalmology<br/><br/>Section 13: Anesthesia<br/>59 Local Anesthesia<br/>60 General Anesthesia and Sedation<br/>61 Treatment of Pain<br/><br/>Section 14: Hematologic Therapeutics<br/>62 Anemias and Cytopenias<br/>63 Disorders of Hemostasis and Thrombosis<br/><br/>Section 15: Oncologic Therapeutics<br/>64 Lung Cancer<br/>65 Breast Cancer<br/>66 Hematologic Malignancies<br/>67 Prostate Cancer<br/>68 Colon Cancer<br/>69 Melanoma<br/><br/>Section 16: Dermatologic Therapeutics<br/>70 Acne<br/>71 Psoriasis<br/>72 Dermatitis<br/><br/>Section 17: Rheumatologic Therapeutics<br/>73 Osteoarthritis<br/>74 Rheumatoid Arthritis<br/>75 Gout<br/>76 Systemic Lupus Erythmatosus<br/><br/>Section 18: Therapy of Infectious Diseases<br/>77 Influenza and Viral Respiratory Infections<br/>78 Community-Acquired Pneumonia<br/>79 Tuberculosis<br/>80 Bacterial Meningitis<br/>81 Endocarditis<br/>82 Malaria<br/>83 Protozoan and Helminthic Infections<br/>84 HIV Infection and AIDS85 Sexually Transmitted Diseases<br/><br/>Section 19: Practical Therapeutics<br/>86 Medical Toxicology and Antidotes<br/>87 Over-the-Counter Medications<br/>88 Prescription and Order Writing<br/>89 Pharmacy and Therapeutics Committees and the Hospital Formulary<br/><br/>Section 20: Emerging Therapeutics<br/>90 "Complementary and Alternative Medicine, Nutraceuticals, and Dietary Supplements"<br/>91 Vaccines<br/>92 Transplant Medicine<br/>93 Gene Therapy<br/>94 Regenerative Medicine and Stem Cell Therapeutics |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Pharmacology. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Chemotherapy. |
| 650 12 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Pharmacology, Clinical |
| General subdivision |
methods. |
| 650 22 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Drug Therapy. |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Terzic, Andre. |
| 906 ## - LOCAL DATA ELEMENT F, LDF (RLIN) |
|---|
| a |
7 |
| b |
cbc |
| c |
orignew |
| d |
1 |
| e |
ecip |
| f |
20 |
| g |
y-gencatlg |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Dewey Decimal Classification |
| Koha item type |
Book Open Access |
| Classification part |
QV 4 |
| Item part |
1 |
| Call number prefix |
W164p 2009 |
| Call number suffix |
QV 4 W164p 2009 |
